You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameSufentanil
Accession NumberDB00708  (APRD00671)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionAn opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent. [PubChem]
Structure
Thumb
Synonyms
N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidinyl)-N-phenylpropanamide
N-(4-(Methoxymethyl)-1-(2-(2-thienyl)ethyl)-4-piperidyl)propionanilide
Sufentanil
Sufentanilo
Sufentanilum
Sufentanyl
External Identifiers
  • R 30730
  • R 33800
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Sufenta Inj 50mcg/mlLiquid50 mcgEpidural; IntravenousJanssen Inc1985-12-312007-11-26Canada
Sufenta Inj 50mcg/mlLiquid50 mcgIntravenousJanssen Pharmaceutica, Division Of Janssen Ortho Inc.1985-12-311996-09-10Canada
Sufentanil CitrateInjection50 ug/mLEpidural; IntravenousAkorn, Inc.2010-12-01Not applicableUs
Sufentanil Citrate Injection USPSolution50 mcgEpidural; IntravenousSandoz Canada Incorporated2001-08-01Not applicableCanada
Sufentanil Citrate Injection, USPSolution50 mcgEpidural; IntravenousSterimax Inc2016-10-18Not applicableCanada
ZalvisoTablet15 μgSublingualGrunenthal Gmb H2015-09-18Not applicableEu
ZalvisoTablet15 μgSublingualGrunenthal Gmb H2015-09-18Not applicableEu
ZalvisoTablet15 μgSublingualGrunenthal Gmb H2015-09-18Not applicableEu
ZalvisoTablet15 μgSublingualGrunenthal Gmb H2015-09-18Not applicableEu
ZalvisoTablet15 μgSublingualGrunenthal Gmb H2015-09-18Not applicableEu
ZalvisoTablet15 μgSublingualGrunenthal Gmb H2015-09-18Not applicableEu
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Sufentanil CitrateInjection.05 mg/mLEpidural; IntravenousWest Ward Pharmaceutical Corp.1995-12-15Not applicableUs
Sufentanil CitrateInjection, solution50 ug/mLEpidural; IntravenousHospira, Inc.1996-12-11Not applicableUs
Sufentanil CitrateInjection.05 mg/mLEpidural; IntravenousWest Ward Pharmaceutical Corp.1995-12-15Not applicableUs
Sufentanil CitrateInjection.05 mg/mLEpidural; IntravenousWest Ward Pharmaceutical Corp.1995-12-15Not applicableUs
Sufentanil CitrateInjection, solution50 ug/mLEpidural; IntravenousHospira, Inc.1996-12-11Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ChronogesicDURECT
DisufenAngenerico
FastfenCristália
SufentaJanssen
Sufenta ForteJanssen
Sufenta miteJanssen
SufentilClaris Lifesciences Ltd.
ZuftilPisa
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Sufentanil Citrate
Thumb
  • InChI Key: OJCZPLDERGDQRJ-UHFFFAOYSA-N
  • Monoisotopic Mass: 578.229801514
  • Average Mass: 578.674
DBSALT000275
Categories
UNIIAFE2YW0IIZ
CAS number56030-54-7
WeightAverage: 386.551
Monoisotopic: 386.202798904
Chemical FormulaC22H30N2O2S
InChI KeyGGCSSNBKKAUURC-UHFFFAOYSA-N
InChI
InChI=1S/C22H30N2O2S/c1-3-21(25)24(19-8-5-4-6-9-19)22(18-26-2)12-15-23(16-13-22)14-11-20-10-7-17-27-20/h4-10,17H,3,11-16,18H2,1-2H3
IUPAC Name
N-[4-(methoxymethyl)-1-[2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropanamide
SMILES
CCC(=O)N(C1=CC=CC=C1)C1(COC)CCN(CCC2=CC=CS2)CC1
Pharmacology
IndicationUsed as an analgesic adjunct in anesthesia and as a primary anesthetic drug in procedures requiring assisted ventilation and in the relief of pain.
Structured Indications Not Available
PharmacodynamicsSufentanil is a synthetic opioid analgesic. Sufentanil interacts predominately with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, spinal cord, and other tissues. In clinical settings, sufentanil exerts its principal pharmacologic effects on the central nervous system. Its primary actions of therapeutic value are analgesia and sedation. Sufentanil may increase the patient's tolerance for pain and decrease the perception of suffering, although the presence of the pain itself may still be recognized. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. Sufentanil depresses the respiratory centers, depresses the cough reflex, and constricts the pupils.
Mechanism of actionOpiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Sufentanil's analgesic activity is, most likely, due to its conversion to morphine. Opioids open calcium-dependent inwardly rectifying potassium channels (OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability.
TargetKindPharmacological actionActionsOrganismUniProt ID
Mu-type opioid receptorProteinyes
agonist
HumanP35372 details
Delta-type opioid receptorProteinunknown
agonist
HumanP41143 details
Kappa-type opioid receptorProteinunknown
other
HumanP41145 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half life265 minutes
ClearanceNot Available
ToxicityLD50: 18.7 mg/kg (IV in mice)
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Sufentanil Action PathwayDrug actionSMP00417
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Sufentanil is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetamine2,5-Dimethoxy-4-ethylamphetamine may increase the analgesic activities of Sufentanil.Experimental, Illicit
3,4-Methylenedioxyamphetamine3,4-Methylenedioxyamphetamine may increase the analgesic activities of Sufentanil.Experimental, Illicit
3,4-Methylenedioxymethamphetamine3,4-Methylenedioxymethamphetamine may increase the analgesic activities of Sufentanil.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine4-Bromo-2,5-dimethoxyamphetamine may increase the analgesic activities of Sufentanil.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when Sufentanil is combined with 7-Nitroindazole.Experimental
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINESufentanil may increase the serotonergic activities of 7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE.Experimental
AcebutololSufentanil may increase the bradycardic activities of Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Aceprometazine.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Acetazolamide.Approved, Vet Approved
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Sufentanil.Approved
adipiplonThe risk or severity of adverse effects can be increased when Sufentanil is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Agomelatine.Approved, Investigational
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Sufentanil.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Alfentanil.Approved, Illicit
AlimemazineAlimemazine may increase the hypotensive activities of Sufentanil.Approved, Vet Approved
AliskirenThe risk or severity of adverse effects can be increased when Aliskiren is combined with Sufentanil.Approved, Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Sufentanil.Approved, Illicit, Investigational
AlprenololSufentanil may increase the bradycardic activities of Alprenolol.Approved, Withdrawn
AlvimopanThe risk or severity of adverse effects can be increased when Sufentanil is combined with Alvimopan.Approved
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Sufentanil.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Amiloride.Approved
AmiodaroneThe metabolism of Sufentanil can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Amitriptyline.Approved
AmlodipineThe risk or severity of adverse effects can be increased when Amlodipine is combined with Sufentanil.Approved
Ammonium chlorideAmmonium chloride may increase the excretion rate of Sufentanil which could result in a lower serum level and potentially a reduction in efficacy.Approved, Vet Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Sufentanil is combined with Amobarbital.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Amperozide.Experimental
AmphetamineAmphetamine may increase the analgesic activities of Sufentanil.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Sufentanil.Approved, Investigational
Amyl NitriteThe risk or severity of adverse effects can be increased when Amyl Nitrite is combined with Sufentanil.Approved
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Sufentanil.Approved
Aop200704Sufentanil may increase the bradycardic activities of Aop200704.Investigational
ApomorphineThe risk or severity of adverse effects can be increased when Apomorphine is combined with Sufentanil.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Apraclonidine is combined with Sufentanil.Approved
AprepitantThe serum concentration of Sufentanil can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the hypotensive activities of Sufentanil.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Sufentanil.Approved
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Sufentanil.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Asenapine.Approved
AtazanavirThe metabolism of Sufentanil can be decreased when combined with Atazanavir.Approved, Investigational
AtenololAtenolol may increase the bradycardic activities of Sufentanil.Approved
AtomoxetineThe metabolism of Sufentanil can be decreased when combined with Atomoxetine.Approved
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Sufentanil.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Sufentanil.Approved, Vet Approved
AzaperoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Azaperone.Vet Approved
AzelastineSufentanil may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Sufentanil.Approved
AzosemideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Azosemide.Investigational
BaclofenThe risk or severity of adverse effects can be increased when Sufentanil is combined with Baclofen.Approved
BarbexacloneBarbexaclone may increase the hypotensive activities of Sufentanil.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Sufentanil is combined with Barbital.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Sufentanil.Approved
BefunololSufentanil may increase the bradycardic activities of Befunolol.Experimental
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Sufentanil.Withdrawn
BenazeprilThe risk or severity of adverse effects can be increased when Benazepril is combined with Sufentanil.Approved, Investigational
BendroflumethiazideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Bendroflumethiazide.Approved
BenmoxinSufentanil may increase the serotonergic activities of Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Benperidol.Investigational
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Sufentanil.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Benzocaine.Approved
BenzphetamineBenzphetamine may increase the analgesic activities of Sufentanil.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Sufentanil is combined with Benzyl alcohol.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Sufentanil.Approved, Withdrawn
BeractantSufentanil may increase the bradycardic activities of Beractant.Approved
BetaxololBetaxolol may increase the bradycardic activities of Sufentanil.Approved
BevantololSufentanil may increase the bradycardic activities of Bevantolol.Approved
BexaroteneThe serum concentration of Sufentanil can be decreased when it is combined with Bexarotene.Approved, Investigational
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Sufentanil.Approved
BisoprololBisoprolol may increase the bradycardic activities of Sufentanil.Approved
BL-1020BL-1020 may increase the hypotensive activities of Sufentanil.Investigational
BoceprevirThe metabolism of Sufentanil can be decreased when combined with Boceprevir.Approved
BopindololSufentanil may increase the bradycardic activities of Bopindolol.Approved
BortezomibThe metabolism of Sufentanil can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Sufentanil can be decreased when it is combined with Bosentan.Approved, Investigational
BretyliumBretylium may increase the bradycardic activities of Sufentanil.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Sufentanil is combined with Brexpiprazole.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.Approved
BromazepamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Bromazepam.Approved, Illicit
BromocriptineThe risk or severity of adverse effects can be increased when Bromocriptine is combined with Sufentanil.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Brotizolam.Approved, Withdrawn
BucindololSufentanil may increase the bradycardic activities of Bucindolol.Investigational
BufuralolSufentanil may increase the bradycardic activities of Bufuralol.Experimental, Investigational
BumetanideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Bumetanide.Approved
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Sufentanil.Approved, Investigational
BupranololSufentanil may increase the bradycardic activities of Bupranolol.Approved
BuprenorphineSufentanil may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Sufentanil.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Sufentanil.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Sufentanil is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Sufentanil is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Sufentanil is combined with Butethal.Approved, Illicit
ButorphanolButorphanol may decrease the analgesic activities of Sufentanil.Approved, Illicit, Vet Approved
CalfactantSufentanil may increase the bradycardic activities of Calfactant.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Canagliflozin is combined with Sufentanil.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Sufentanil.Approved
Canrenoic acidThe risk or severity of adverse effects can be increased when Sufentanil is combined with Canrenoic acid.Approved, Withdrawn
CanrenoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Canrenone.Investigational
CaptoprilThe risk or severity of adverse effects can be increased when Captopril is combined with Sufentanil.Approved
CarbamazepineThe metabolism of Sufentanil can be increased when combined with Carbamazepine.Approved, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Sufentanil.Approved
CarbinoxamineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Carisoprodol.Approved
CaroxazoneSufentanil may increase the serotonergic activities of Caroxazone.Withdrawn
CarteololCarteolol may increase the bradycardic activities of Sufentanil.Approved
CarvedilolSufentanil may increase the bradycardic activities of Carvedilol.Approved, Investigational
CeliprololSufentanil may increase the bradycardic activities of Celiprolol.Approved, Investigational
CeritinibSufentanil may increase the bradycardic activities of Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Sufentanil is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Sufentanil.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Chloroprocaine.Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorphenamine.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Sufentanil.Withdrawn
ChlorphentermineChlorphentermine may increase the analgesic activities of Sufentanil.Illicit, Withdrawn
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Sufentanil.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorprothixene.Approved, Withdrawn
ChlorthalidoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorthalidone.Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Chlorzoxazone.Approved
CicletanineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Cicletanine.Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Cilazapril is combined with Sufentanil.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Sufentanil.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Sufentanil.Approved, Vet Approved
CitalopramSufentanil may increase the serotonergic activities of Citalopram.Approved
ClarithromycinThe metabolism of Sufentanil can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Sufentanil can be decreased when combined with Clemastine.Approved
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Sufentanil.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Sufentanil is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Sufentanil.Approved, Investigational
clomethiazoleThe risk or severity of adverse effects can be increased when Sufentanil is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Clonazepam.Approved, Illicit
ClonidineClonidine may increase the bradycardic activities of Sufentanil.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Sufentanil.Approved, Illicit
ClotrimazoleThe metabolism of Sufentanil can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Sufentanil.Approved
CobicistatThe metabolism of Sufentanil can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Cocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Sufentanil.Approved, Illicit
ConivaptanThe serum concentration of Sufentanil can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe metabolism of Sufentanil can be decreased when combined with Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Cyclobenzaprine.Approved
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Sufentanil.Approved
CyclosporineThe metabolism of Sufentanil can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Cyclothiazide.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Cyproheptadine.Approved
DabrafenibThe serum concentration of Sufentanil can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dantrolene.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Dapagliflozin is combined with Sufentanil.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Sufentanil.Approved
DapoxetineSufentanil may increase the serotonergic activities of Dapoxetine.Investigational
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Sufentanil.Approved, Investigational
DarunavirThe metabolism of Sufentanil can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Sufentanil can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Sufentanil can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Sufentanil can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Sufentanil is combined with deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Desflurane.Approved
DesipramineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Desloratadine.Approved, Investigational
DesmopressinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Desmopressin.Approved
DesvenlafaxineSufentanil may increase the serotonergic activities of Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Sufentanil can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dexbrompheniramine.Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Sufentanil.Withdrawn
DexmedetomidineDexmedetomidine may increase the bradycardic activities of Sufentanil.Approved, Vet Approved
DextroamphetamineDextroamphetamine may increase the analgesic activities of Sufentanil.Approved, Illicit
DextromoramideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Sufentanil.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Diazepam.Approved, Illicit, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Diclofenamide is combined with Sufentanil.Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Sufentanil.Approved
DiethylpropionDiethylpropion may increase the analgesic activities of Sufentanil.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Difenoxin.Approved, Illicit
DigoxinDigoxin may increase the bradycardic activities of Sufentanil.Approved
DihydrocodeineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe metabolism of Sufentanil can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Sufentanil can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Sufentanil is combined with Dimenhydrinate.Approved
DinutuximabThe risk or severity of adverse effects can be increased when Dinutuximab is combined with Sufentanil.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Diphenhydramine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Sufentanil is combined with Diphenoxylate.Approved, Illicit
DipyridamoleThe risk or severity of adverse effects can be increased when Dipyridamole is combined with Sufentanil.Approved
DonepezilSufentanil may increase the bradycardic activities of Donepezil.Approved
DoramectinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Doramectin.Vet Approved
DoxazosinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Sufentanil.Approved
DoxepinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Doxepin.Approved
DoxycyclineThe metabolism of Sufentanil can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Sufentanil is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.Approved, Illicit
DronedaroneThe metabolism of Sufentanil can be decreased when combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.Approved, Vet Approved
DrospirenoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Drospirenone.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Drotebanol.Experimental, Illicit
DuloxetineSufentanil may increase the orthostatic hypotensive activities of Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Sufentanil.Approved
EcgonineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Sufentanil is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Sufentanil can be decreased when it is combined with Efavirenz.Approved, Investigational
EfonidipineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Efonidipine.Approved
EluxadolineSufentanil may increase the constipating activities of Eluxadoline.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Empagliflozin is combined with Sufentanil.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Enalapril is combined with Sufentanil.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Enalaprilat is combined with Sufentanil.Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Sufentanil.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Sufentanil is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Sufentanil can be decreased when it is combined with Enzalutamide.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Epoprostenol is combined with Sufentanil.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Sufentanil.Approved
ErythromycinThe metabolism of Sufentanil can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramSufentanil may increase the serotonergic activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Sufentanil can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmololEsmolol may increase the bradycardic activities of Sufentanil.Approved
EstazolamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Sufentanil.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Sufentanil is combined with Etacrynic acid.Approved
EthanolSufentanil may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Sufentanil.Approved, Illicit, Withdrawn
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Sufentanil.Approved
EthosuximideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ethotoin.Approved
EthoxzolamideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ethoxzolamide.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Sufentanil.Approved
EtoperidoneSufentanil may increase the serotonergic activities of Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Sufentanil can be decreased when it is combined with Etravirine.Approved
EzogabineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Sufentanil is combined with Felbamate.Approved
FelodipineThe risk or severity of adverse effects can be increased when Felodipine is combined with Sufentanil.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Fenoldopam is combined with Sufentanil.Approved
FentanylThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe risk or severity of adverse effects can be increased when Fesoterodine is combined with Sufentanil.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fexofenadine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Sufentanil.Approved
FingolimodSufentanil may increase the bradycardic activities of Fingolimod.Approved, Investigational
FlibanserinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Flibanserin.Approved
FluconazoleThe metabolism of Sufentanil can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Flunitrazepam.Approved, Illicit
FluoxetineSufentanil may increase the serotonergic activities of Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Flupentixol.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Sufentanil.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Sufentanil.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fluticasone Propionate.Approved
FluvoxamineThe metabolism of Sufentanil can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe metabolism of Sufentanil can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Sufentanil can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe risk or severity of adverse effects can be increased when Fosinopril is combined with Sufentanil.Approved
FosphenytoinThe metabolism of Sufentanil can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Fospropofol.Approved, Illicit
FurazolidoneSufentanil may increase the serotonergic activities of Furazolidone.Approved, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Sufentanil can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Sufentanil is combined with gabapentin enacarbil.Approved
GalantamineGalantamine may increase the bradycardic activities of Sufentanil.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Sufentanil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Sufentanil is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Sufentanil is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Glutethimide.Approved, Illicit
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Sufentanil.Approved, Investigational, Vet Approved
GuanfacineSufentanil may increase the bradycardic activities of Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Halazepam.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Sufentanil.Approved
HalothaneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Halothane.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Heroin.Approved, Illicit
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Sufentanil.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Sufentanil is combined with Hexobarbital.Approved
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Sufentanil.Approved
HydracarbazineSufentanil may increase the serotonergic activities of Hydracarbazine.Approved
HydralazineThe risk or severity of adverse effects can be increased when Hydralazine is combined with Sufentanil.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneSufentanil may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydroflumethiazideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Hydroflumethiazide.Approved
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Sufentanil.Approved, Illicit
Hydroxyamphetamine hydrobromideHydroxyamphetamine hydrobromide may increase the analgesic activities of Sufentanil.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.Approved
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Sufentanil.Approved
IdelalisibThe serum concentration of Sufentanil can be increased when it is combined with Idelalisib.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Iloprost is combined with Sufentanil.Approved, Investigational
ImatinibThe metabolism of Sufentanil can be decreased when combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Sufentanil.Investigational
ImipramineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Imipramine.Approved
IndalpineSufentanil may increase the serotonergic activities of Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Indapamide.Approved
IndenololSufentanil may increase the bradycardic activities of Indenolol.Withdrawn
IndinavirThe metabolism of Sufentanil can be decreased when combined with Indinavir.Approved
IndoraminThe risk or severity of adverse effects can be increased when Indoramin is combined with Sufentanil.Withdrawn
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Sufentanil.Approved
IproclozideSufentanil may increase the serotonergic activities of Iproclozide.Withdrawn
IproniazidSufentanil may increase the serotonergic activities of Iproniazid.Withdrawn
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Sufentanil.Approved, Investigational
IsavuconazoniumThe metabolism of Sufentanil can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidSufentanil may increase the serotonergic activities of Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Isoflurane.Approved, Vet Approved
IsosorbideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Isosorbide.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Isosorbide Dinitrate is combined with Sufentanil.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Isosorbide Mononitrate is combined with Sufentanil.Approved
IsoxsuprineThe risk or severity of adverse effects can be increased when Isoxsuprine is combined with Sufentanil.Approved, Withdrawn
IsradipineThe metabolism of Sufentanil can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Sufentanil can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineSufentanil may increase the bradycardic activities of Ivabradine.Approved
IvacaftorThe serum concentration of Sufentanil can be increased when it is combined with Ivacaftor.Approved
KetamineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ketobemidone.Approved
KetoconazoleThe metabolism of Sufentanil can be decreased when combined with Ketoconazole.Approved, Investigational
KW-3902The risk or severity of adverse effects can be increased when Sufentanil is combined with KW-3902.Investigational
LabetalolLabetalol may increase the bradycardic activities of Sufentanil.Approved
LacidipineThe risk or severity of adverse effects can be increased when Lacidipine is combined with Sufentanil.Approved
LacosamideSufentanil may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Lamotrigine.Approved, Investigational
LanreotideSufentanil may increase the bradycardic activities of Lanreotide.Approved
LercanidipineThe risk or severity of adverse effects can be increased when Lercanidipine is combined with Sufentanil.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Levetiracetam.Approved, Investigational
LevobunololSufentanil may increase the bradycardic activities of Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Levocetirizine.Approved
LevodopaSufentanil may increase the orthostatic hypotensive activities of Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Sufentanil is combined with Levomethadyl Acetate.Approved
LevomilnacipranSufentanil may increase the serotonergic activities of Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Levorphanol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Sufentanil.Approved, Investigational
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Sufentanil.Approved, Vet Approved
LisdexamfetamineLisdexamfetamine may increase the analgesic activities of Sufentanil.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Lisinopril is combined with Sufentanil.Approved, Investigational
LithiumThe risk or severity of adverse effects can be increased when Sufentanil is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Lofentanil.Illicit
LofexidineThe risk or severity of adverse effects can be increased when Lofexidine is combined with Sufentanil.Approved, Investigational
LopinavirThe metabolism of Sufentanil can be decreased when combined with Lopinavir.Approved
LoratadineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Sufentanil.Approved
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Sufentanil.Approved
LovastatinThe metabolism of Sufentanil can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Sufentanil.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Sufentanil is combined with Lu AA21004.Investigational
LucinactantSufentanil may increase the bradycardic activities of Lucinactant.Approved
LuliconazoleThe serum concentration of Sufentanil can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Sufentanil can be increased when combined with Lumacaftor.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Lurasidone.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.Approved, Vet Approved
MannitolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Mannitol.Approved, Investigational
MaprotilineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Maprotiline.Approved
MebanazineSufentanil may increase the serotonergic activities of Mebanazine.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Sufentanil.Approved
MeclizineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Sufentanil is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Melperone.Approved
MephedroneMephedrone may increase the analgesic activities of Sufentanil.Investigational
MephentermineMephentermine may increase the analgesic activities of Sufentanil.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Sufentanil.Approved, Illicit
MersalylThe risk or severity of adverse effects can be increased when Sufentanil is combined with Mersalyl.Approved
MesoridazineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Mesoridazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Sufentanil.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineMethamphetamine may increase the analgesic activities of Sufentanil.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Sufentanil.Approved
MethapyrileneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methaqualone.Illicit, Withdrawn
MethazolamideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methazolamide.Approved
MethocarbamolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Sufentanil.Approved
MethotrimeprazineSufentanil may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methoxyflurane.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methyclothiazide.Approved
MethyldopaSufentanil may increase the bradycardic activities of Methyldopa.Approved
Methylene blueSufentanil may increase the serotonergic activities of Methylene blue.Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methylphenobarbital.Approved
MetipranololSufentanil may increase the bradycardic activities of Metipranolol.Approved
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Sufentanil.Approved
MetolazoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Metolazone.Approved
MetoprololMetoprolol may increase the bradycardic activities of Sufentanil.Approved, Investigational
MetyrosineSufentanil may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Sufentanil.Approved, Illicit
MifepristoneThe serum concentration of Sufentanil can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranSufentanil may increase the serotonergic activities of Milnacipran.Approved
MinaprineSufentanil may increase the serotonergic activities of Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.Approved, Investigational
MinoxidilThe risk or severity of adverse effects can be increased when Minoxidil is combined with Sufentanil.Approved
MirtazapineSufentanil may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Sufentanil can be decreased when it is combined with Mitotane.Approved
MMDAMMDA may increase the analgesic activities of Sufentanil.Experimental, Illicit
MoclobemideSufentanil may increase the serotonergic activities of Moclobemide.Approved
ModafinilThe serum concentration of Sufentanil can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Moexipril is combined with Sufentanil.Approved
MolindoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Molindone.Approved
MoricizineMoricizine may increase the hypotensive activities of Sufentanil.Approved, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Sufentanil.Approved, Investigational
MoxonidineThe risk or severity of adverse effects can be increased when Moxonidine is combined with Sufentanil.Approved
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Sufentanil.Vet Approved
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.Approved, Investigational
NadololSufentanil may increase the bradycardic activities of Nadolol.Approved
NafcillinThe serum concentration of Sufentanil can be decreased when it is combined with Nafcillin.Approved
NalbuphineNalbuphine may decrease the analgesic activities of Sufentanil.Approved
NaltrexoneThe therapeutic efficacy of Sufentanil can be decreased when used in combination with Naltrexone.Approved, Investigational, Vet Approved
NebivololSufentanil may increase the bradycardic activities of Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Sufentanil can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Sufentanil can be decreased when combined with Nelfinavir.Approved
NesiritideThe risk or severity of adverse effects can be increased when Nesiritide is combined with Sufentanil.Approved, Investigational
NetupitantThe serum concentration of Sufentanil can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Sufentanil can be increased when combined with Nevirapine.Approved
NialamideSufentanil may increase the serotonergic activities of Nialamide.Withdrawn
NicardipineThe risk or severity of adverse effects can be increased when Nicardipine is combined with Sufentanil.Approved
NicorandilNicorandil may increase the hypotensive activities of Sufentanil.Approved
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Sufentanil.Approved
NilotinibThe metabolism of Sufentanil can be decreased when combined with Nilotinib.Approved, Investigational
NilvadipineThe risk or severity of adverse effects can be increased when Nilvadipine is combined with Sufentanil.Approved
NimodipineThe risk or severity of adverse effects can be increased when Nimodipine is combined with Sufentanil.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Nisoldipine is combined with Sufentanil.Approved
NitrazepamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Nitrazepam.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Sufentanil.Approved
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Sufentanil.Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Nitroglycerin is combined with Sufentanil.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Nitroprusside is combined with Sufentanil.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Nitrous oxide.Approved, Vet Approved
NormethadoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Nortriptyline.Approved
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Sufentanil.Investigational
ObinutuzumabThe risk or severity of adverse effects can be increased when Obinutuzumab is combined with Sufentanil.Approved
OctamoxinSufentanil may increase the serotonergic activities of Octamoxin.Withdrawn
OctreotideOctreotide may increase the bradycardic activities of Sufentanil.Approved, Investigational
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Sufentanil.Approved, Investigational
OlaparibThe metabolism of Sufentanil can be decreased when combined with Olaparib.Approved
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Sufentanil.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Sufentanil is combined with Opium.Approved, Illicit
OrphenadrineSufentanil may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Sufentanil is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Sufentanil can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Oxazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Sufentanil is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Oxybuprocaine.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Sufentanil.Approved, Investigational
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Sufentanil.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Sufentanil.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Sufentanil.Approved, Vet Approved
PalbociclibThe serum concentration of Sufentanil can be increased when it is combined with Palbociclib.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Paliperidone.Approved
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Sufentanil.Approved
PapaverineThe risk or severity of adverse effects can be increased when Papaverine is combined with Sufentanil.Approved
ParaldehydeSufentanil may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
PargylineSufentanil may increase the serotonergic activities of Pargyline.Approved
ParoxetineSufentanil may increase the serotonergic activities of Paroxetine.Approved, Investigational
PasireotideSufentanil may increase the bradycardic activities of Pasireotide.Approved
PegvisomantThe therapeutic efficacy of Pegvisomant can be decreased when used in combination with Sufentanil.Approved
PenbutololSufentanil may increase the bradycardic activities of Penbutolol.Approved, Investigational
PentazocinePentazocine may decrease the analgesic activities of Sufentanil.Approved, Vet Approved
PentobarbitalThe metabolism of Sufentanil can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Sufentanil.Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.Approved
PerazineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Perazine.Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Perindopril is combined with Sufentanil.Approved
PerospironeThe risk or severity of adverse effects can be increased when Sufentanil is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Perphenazine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Sufentanil.Approved
PhenelzineSufentanil may increase the serotonergic activities of Phenelzine.Approved
PheniprazineSufentanil may increase the serotonergic activities of Pheniprazine.Withdrawn
PhenobarbitalThe metabolism of Sufentanil can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineThe risk or severity of adverse effects can be increased when Phenoxybenzamine is combined with Sufentanil.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Phenoxyethanol.Approved
PhenoxypropazineSufentanil may increase the serotonergic activities of Phenoxypropazine.Withdrawn
PhenterminePhentermine may increase the analgesic activities of Sufentanil.Approved, Illicit
PhentolamineThe risk or severity of adverse effects can be increased when Phentolamine is combined with Sufentanil.Approved
PhenytoinThe metabolism of Sufentanil can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Pimozide.Approved
PindololSufentanil may increase the bradycardic activities of Pindolol.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Pipamperone.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Sufentanil.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Pipotiazine.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Sufentanil.Approved
PiretanideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Piretanide.Experimental
PiritramideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Piritramide.Investigational
PirlindoleSufentanil may increase the serotonergic activities of Pirlindole.Approved
PivhydrazineSufentanil may increase the serotonergic activities of Pivhydrazine.Withdrawn
PizotifenThe risk or severity of adverse effects can be increased when Sufentanil is combined with Pizotifen.Approved
PolythiazideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Polythiazide.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Pomalidomide.Approved
Poractant alfaSufentanil may increase the bradycardic activities of Poractant alfa.Approved
PosaconazoleThe metabolism of Sufentanil can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PotassiumThe risk or severity of adverse effects can be increased when Sufentanil is combined with Potassium.Approved
Potassium CitrateThe risk or severity of adverse effects can be increased when Sufentanil is combined with Potassium Citrate.Approved, Vet Approved
PractololSufentanil may increase the bradycardic activities of Practolol.Approved
PramipexoleSufentanil may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Prazepam.Approved, Illicit
PrazosinThe risk or severity of adverse effects can be increased when Prazosin is combined with Sufentanil.Approved
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Sufentanil.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Prilocaine.Approved
PrimidoneThe metabolism of Sufentanil can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Procaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Sufentanil.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Sufentanil.Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Sufentanil.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Promethazine.Approved
PropafenoneSufentanil may increase the bradycardic activities of Propafenone.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Sufentanil.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Proparacaine.Approved, Vet Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Sufentanil.Vet Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Sufentanil.Investigational
PropofolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Propofol.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Propoxycaine.Approved
PropranololPropranolol may increase the bradycardic activities of Sufentanil.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Protriptyline.Approved
PSD502The risk or severity of adverse effects can be increased when Sufentanil is combined with PSD502.Investigational
PseudoephedrinePseudoephedrine may increase the analgesic activities of Sufentanil.Approved
QuazepamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Quazepam.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Quinapril is combined with Sufentanil.Approved, Investigational
QuinethazoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Quinethazone.Approved
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Sufentanil.Approved
RacloprideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ramelteon.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Sufentanil.Approved
RamosetronSufentanil may increase the constipating activities of Ramosetron.Approved
RanolazineThe metabolism of Sufentanil can be decreased when combined with Ranolazine.Approved, Investigational
RasagilineSufentanil may increase the serotonergic activities of Rasagiline.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Sufentanil.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Sufentanil.Approved
RifabutinThe metabolism of Sufentanil can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Sufentanil can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Sufentanil can be increased when combined with Rifapentine.Approved
RiociguatThe risk or severity of adverse effects can be increased when Riociguat is combined with Sufentanil.Approved
RisperidoneSufentanil may increase the hypotensive activities of Risperidone.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ritanserin.Investigational
RitobegronRitobegron may increase the analgesic activities of Sufentanil.Investigational
RitonavirThe metabolism of Sufentanil can be decreased when combined with Ritonavir.Approved, Investigational
RivastigmineSufentanil may increase the bradycardic activities of Rivastigmine.Approved, Investigational
RolofyllineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Rolofylline.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Romifidine.Vet Approved
RopiniroleSufentanil may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Sufentanil.Approved
RotigotineSufentanil may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Sufentanil.Approved
RuxolitinibRuxolitinib may increase the bradycardic activities of Sufentanil.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Sufentanil is combined with S-Ethylisothiourea.Experimental
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Sufentanil.Approved
SafrazineSufentanil may increase the serotonergic activities of Safrazine.Withdrawn
Sage 547The risk or severity of adverse effects can be increased when Sufentanil is combined with Sage 547.Investigational
SaquinavirThe metabolism of Sufentanil can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Scopolamine.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Sufentanil.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Sufentanil.Approved, Vet Approved
SelegilineSufentanil may increase the serotonergic activities of Selegiline.Approved, Investigational, Vet Approved
SertindoleThe risk or severity of adverse effects can be increased when Sufentanil is combined with Sertindole.Approved, Withdrawn
SertralineSufentanil may increase the serotonergic activities of Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Sevoflurane.Approved, Vet Approved
SildenafilThe metabolism of Sufentanil can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Sufentanil can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Sufentanil can be increased when it is combined with Simeprevir.Approved
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Sufentanil.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.Approved
SolifenacinThe risk or severity of adverse effects can be increased when Solifenacin is combined with Sufentanil.Approved
SotalolSotalol may increase the bradycardic activities of Sufentanil.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Spironolactone.Approved
St. John's WortThe serum concentration of Sufentanil can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Sufentanil can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Sufentanil.Approved
SuccinylcholineSuccinylcholine may increase the bradycardic activities of Sufentanil.Approved
SulfisoxazoleThe metabolism of Sufentanil can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Sufentanil.Approved
SuvorexantSufentanil may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TamsulosinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tamsulosin.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tasimelteon.Approved
TelaprevirThe metabolism of Sufentanil can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Sufentanil can be decreased when combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Sufentanil.Approved, Investigational
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Sufentanil.Approved
TerazosinThe risk or severity of adverse effects can be increased when Terazosin is combined with Sufentanil.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tetrodotoxin.Investigational
ThalidomideSufentanil may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheobromineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Theobromine.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Sufentanil is combined with Thiamylal.Approved, Vet Approved
ThiethylperazineThiethylperazine may increase the hypotensive activities of Sufentanil.Withdrawn
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Sufentanil.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Sufentanil.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Thiothixene.Approved
TiagabineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tiapride.Investigational
TiclopidineThe metabolism of Sufentanil can be decreased when combined with Ticlopidine.Approved
TicrynafenThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ticrynafen.Withdrawn
TiletamineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tiletamine.Vet Approved
TimololTimolol may increase the bradycardic activities of Sufentanil.Approved
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Sufentanil.Approved
TizanidineTizanidine may increase the bradycardic activities of Sufentanil.Approved
TocilizumabThe serum concentration of Sufentanil can be decreased when it is combined with Tocilizumab.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Sufentanil.Approved, Investigational
TolazolineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tolazoline.Approved, Vet Approved
TolcaponeThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tolcapone.Approved, Withdrawn
ToloxatoneSufentanil may increase the serotonergic activities of Toloxatone.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Sufentanil.Approved, Investigational
TolvaptanThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tolvaptan.Approved
TopiramateThe risk or severity of adverse effects can be increased when Sufentanil is combined with Topiramate.Approved
TorasemideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Torasemide.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Sufentanil.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Trandolapril is combined with Sufentanil.Approved
Trans-2-PhenylcyclopropylamineSufentanil may increase the serotonergic activities of Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineSufentanil may increase the serotonergic activities of Tranylcypromine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Sufentanil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Triamterene.Approved
TriazolamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Triazolam.Approved
TrichlormethiazideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Trichlormethiazide.Approved, Vet Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Sufentanil.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Sufentanil.Approved
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Sufentanil.Approved
TrimipramineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Triprolidine.Approved
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Sufentanil.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Sufentanil.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Sufentanil.Approved
Uc1010The risk or severity of adverse effects can be increased when Sufentanil is combined with Uc1010.Investigational
UlaritideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ularitide.Investigational
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Sufentanil.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Sufentanil.Approved, Investigational
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Sufentanil.Approved, Investigational
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Sufentanil.Approved
VenlafaxineThe metabolism of Sufentanil can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Sufentanil can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Sufentanil is combined with Vigabatrin.Approved
VoriconazoleThe metabolism of Sufentanil can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Vortioxetine.Approved
XylazineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Sufentanil is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ziconotide.Approved
ZimelidineSufentanil may increase the serotonergic activities of Zimelidine.Withdrawn
ZiprasidoneThe metabolism of Sufentanil can be decreased when combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Sufentanil is combined with Zolazepam.Vet Approved
ZolpidemSufentanil may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Sufentanil is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Sufentanil is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Sufentanil is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Sufentanil is combined with Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

Jacob Mathew, J. Killgore, “New methods for the synthesis of alfentanil, sufentanil, and remifentanil.” U.S. Patent US20060149071, issued July 06, 2006.

US20060149071
General ReferencesNot Available
External Links
ATC CodesN01AH03
AHFS Codes
  • 28:08.08
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (47.6 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9875
Blood Brain Barrier+0.9886
Caco-2 permeable+0.5201
P-glycoprotein substrateSubstrate0.6673
P-glycoprotein inhibitor IInhibitor0.8275
P-glycoprotein inhibitor IIInhibitor0.8387
Renal organic cation transporterNon-inhibitor0.5594
CYP450 2C9 substrateNon-substrate0.7923
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.713
CYP450 1A2 substrateNon-inhibitor0.8954
CYP450 2C9 inhibitorNon-inhibitor0.7839
CYP450 2D6 inhibitorNon-inhibitor0.8416
CYP450 2C19 inhibitorNon-inhibitor0.5438
CYP450 3A4 inhibitorInhibitor0.6293
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6401
Ames testNon AMES toxic0.7695
CarcinogenicityNon-carcinogens0.8861
BiodegradationNot ready biodegradable0.9724
Rat acute toxicity3.0968 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9793
hERG inhibition (predictor II)Inhibitor0.772
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Akorn inc
  • Baxter healthcare corp anesthesia and critical care
  • Hospira inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
LiquidEpidural; Intravenous50 mcg
LiquidIntravenous50 mcg
InjectionEpidural; Intravenous.05 mg/mL
InjectionEpidural; Intravenous50 ug/mL
Injection, solutionEpidural; Intravenous50 ug/mL
SolutionEpidural; Intravenous50 mcg
TabletSublingual15 μg
Prices
Unit descriptionCostUnit
Sufentanil citrate powder18927.0USD g
Sufenta 50 mcg/ml ampul5.38USD ml
Sufentanil 50 mcg/ml ampul3.92USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point97 °CPhysProp
water solubility76 mg/L (at 25 °C)ROY,SD & FLYNN,GL (1988)
logP3.95SANGSTER (1993)
logS-3.71ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.012 mg/mLALOGPS
logP3.4ALOGPS
logP3.61ChemAxon
logS-4.5ALOGPS
pKa (Strongest Basic)8.86ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area32.78 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity111.42 m3·mol-1ChemAxon
Polarizability43.85 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as anilides. These are organic heterocyclic compounds derived from oxoacids RkE(=O)l(OH)m (l not 0) by replacing an OH group by the NHPh group or derivative formed by ring substitution.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassAnilides
Direct ParentAnilides
Alternative Parents
Substituents
  • Anilide
  • Aralkylamine
  • 4-aminopiperidine
  • Piperidine
  • Heteroaromatic compound
  • Thiophene
  • Tertiary carboxylic acid amide
  • Tertiary aliphatic amine
  • Tertiary amine
  • Carboxamide group
  • Azacycle
  • Organoheterocyclic compound
  • Ether
  • Dialkyl ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Voltage-gated calcium channel activity
Specific Function:
Receptor for endogenous opioids such as beta-endorphin and endomorphin. Receptor for natural and synthetic opioids including morphine, heroin, DAMGO, fentanyl, etorphine, buprenorphin and methadone. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociati...
Gene Name:
OPRM1
Uniprot ID:
P35372
Molecular Weight:
44778.855 Da
References
  1. Hurle MA: Changes in the expression of G protein-coupled receptor kinases and beta-arrestin 2 in rat brain during opioid tolerance and supersensitivity. J Neurochem. 2001 Apr;77(2):486-92. [PubMed:11299311 ]
  2. Levron JC: [Pharmacokinetics and pharmacodynamics of morphinomimetics in the central nervous system]. Agressologie. 1991;32(6-7):318-20. [PubMed:1688220 ]
  3. Ilien B, Galzi JL, Mejean A, Goeldner M, Hirth C: A mu-opioid receptor-filter assay. Rapid estimation of binding affinity of ligands and reversibility of long-lasting ligand-receptor complexes. Biochem Pharmacol. 1988 Oct 15;37(20):3843-51. [PubMed:2847746 ]
  4. Colpaert FC, Leysen JE, Michiels M, van den Hoogen RH: Epidural and intravenous sufentanil in the rat: analgesia, opiate receptor binding, and drug concentrations in plasma and brain. Anesthesiology. 1986 Jul;65(1):41-9. [PubMed:3014923 ]
  5. Leysen JE, Gommeren W: In vitro binding properties of 3H-sufentanil, a superior ligand for the mu-opiate receptor. Arch Int Pharmacodyn Ther. 1982 Dec;260(2):287-9. [PubMed:6131653 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled receptor that functions as receptor for endogenous enkephalins and for a subset of other opioids. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors, such as adenylate cyclase. Signaling leads to the inhibition of adenylate cyclase activity. Inhibits neurot...
Gene Name:
OPRD1
Uniprot ID:
P41143
Molecular Weight:
40368.235 Da
References
  1. Freye E, Latasch L, Portoghese PS: The delta receptor is involved in sufentanil-induced respiratory depression--opioid subreceptors mediate different effects. Eur J Anaesthesiol. 1992 Nov;9(6):457-62. [PubMed:1330549 ]
  2. Zhu J, Xue JC, Law PY, Claude PA, Luo LY, Yin J, Chen C, Liu-Chen LY: The region in the mu opioid receptor conferring selectivity for sufentanil over the delta receptor is different from that over the kappa receptor. FEBS Lett. 1996 Apr 15;384(2):198-202. [PubMed:8612823 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
other
General Function:
Opioid receptor activity
Specific Function:
G-protein coupled opioid receptor that functions as receptor for endogenous alpha-neoendorphins and dynorphins, but has low affinity for beta-endorphins. Also functions as receptor for various synthetic opioids and for the psychoactive diterpene salvinorin A. Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates th...
Gene Name:
OPRK1
Uniprot ID:
P41145
Molecular Weight:
42644.665 Da
References
  1. Zhu J, Xue JC, Law PY, Claude PA, Luo LY, Yin J, Chen C, Liu-Chen LY: The region in the mu opioid receptor conferring selectivity for sufentanil over the delta receptor is different from that over the kappa receptor. FEBS Lett. 1996 Apr 15;384(2):198-202. [PubMed:8612823 ]
  2. Chang HM, Berde CB, Holz GG 4th, Steward GF, Kream RM: Sufentanil, morphine, met-enkephalin, and kappa-agonist (U-50,488H) inhibit substance P release from primary sensory neurons: a model for presynaptic spinal opioid actions. Anesthesiology. 1989 Apr;70(4):672-7. [PubMed:2467589 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23